ReviewResults and problems in cell differentiation2026
The Role of the Endothelium as a Key Regulator of Chronic Transplant Rejection.
Review in Results and problems in cell differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vascular endothelium serves as an indispensable border for the interaction and exchange of molecules and cells between the blood flow and tissues. Upon transplantation, the endothelium of the allograft is the first to come into contact with the recipient's blood and becomes injured by alloreactive and nonalloreactive stimuli. Repetitive injuries lead to severe damage of the endothelium resulting in the development of chronic rejection over time.The objective of this chapter is to highlight recent insights into the most relevant endothelial molecules, mediators, and pathways crucial in the evolvement of chronic organ rejection. We also discuss new avenues of drugs that can diminish or prevent damage to the endothelium leading to an otherwise irreversible development of chronic organ rejection.
Indexed as
Identifiers
41479022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.